Promoting
Safe & Effective
Wound Bed Preparation

Patient-Focused
Biomimicry
Evidence-Based Medicine
brain campus picture
© Thomas Ott, BRAIN Biotech AG
Our Focus

Our Story

The company was born in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company that focuses on harnessing biological diversity to develop innovative solutions.

Meet our team
Management Team
Lee Harle
CHIEF EXECUTIVE OFFICER
Dr. David Goldsmith
CHIEF MEDICAL OFFICER
Dr. Bela Kelety
CHIEF TECHNOLOGY OFFICER
Oliver Schofield
CHIEF FINANCIAL OFFICER
Dr. Kinga Szepeshazi
MEDICAL DIRECTOR
David Fairlamb
DIRECTOR OF REGULATORY AFFAIRS
Meet our team
Board of Directors

Andy Weymann MD
Chairman

A surgeon by background and formerly Chief Medical Officer at Smith & Nephew, Andy brings not only deep sector experience to SolasCure, but also more than 25 years of executive and board experience in global medical device, biopharma & regenerative medicine companies to SolasCure.

Dan Wright
Director

Dan is a highly experienced executive, Chair and board member of public and private companies. Dan was previously a founding partner at NorthEdge Capital, a UK Private Equity firm following an investment career at Callahan Associates, Deutsche Bank and RBS. He serves as SolasCure’s independent Board member.

Adriaan Moelker
Director

Adriaan is the CEO of BRAIN Biotech AG. Before joining BRAIN Biotech AG, he held a wide variety of management positions during his 35-year career with a particular focus on enzymes and  Biotechnology.

Riad Armanious
Director

Riad is the CEO of Eva Pharma, one of the leading specialty pharma companies in Africa. Riad is active in the YPO (Young Presidents Association), the “T20” foundation and Vice Chairman in the Egyptian Industrial Chamber of Pharmaceuticals.

François Fournier
Director

François is CEO & President of HTL Biotechnology, and was before the CEO of Virbac Corp. based in the US. Having served as head of Wound Care (global) and Asia-Pacific at Smith & Nephew, following multiple leadership roles around the world at Nestle Skin Health and Abbott, François brings not only deep sector experience in woundcare but also broad global experience in pharma and multi-business environments, creating and growing markets in North America, Europe, Middle East / Africa, Asia, and Latin America.

Frank Goebel
Director

Frank is the former CFO of BRAIN Biotech AG and was co-CEO at SymbioPharm. Frank brings long executive experience in bio-based industries to Solascure. Prior experience at RBS and ING. 

Jane Hart
Director

Jane is a highly experienced executive in clinical operations and affairs, with more than 25 years of experience in the clinical research industry, including serving as Vice President, Global Clinical Development at 3M. A leader in drug and device research, Jane brings deep experience of shepherding products from concept through to global approvals to Solascure.

Mission & Values

SolasCure is a pioneering biologics company committed to addressing the pressing issue of inadequate debridement, biofilm disruption, and healing solutions for chronic wounds.

Patient-focused

Patient-focused:
we strive to deliver better wound care treatments for patients, improving outcomes and quality of life

Practical & Adoptable

Practical and adoptable:
we work closely with leading clinicians and providers to ensure our cutting edge products can be readily adopted within standards of care and have the largest impact possible

Evidence-based medicine

Evidence-based:
our scientific programme aims to provide targeted therapies that demonstrably relieve suffering and improve outcomes for patients, clinicians and health systems